The Drug Repurposing Market focuses on identifying new therapeutic uses for medicines that have already been developed, tested, or approved for other indications. Instead of starting drug development from the earliest discovery stages, repurposing allows pharmaceutical and biotechnology companies to investigate existing molecules for new diseases and patient populations. This approach can reduce development time, lower research costs, and make use of established safety and pharmacological data.
The market is gaining importance as pharmaceutical companies look for more efficient approaches to pipeline development and as computational technologies make it easier to identify promising drug-disease connections. Artificial intelligence, machine learning, network pharmacology, real-world evidence, and advanced data analytics are increasingly being incorporated into drug repurposing programs. The global market is estimated at USD 39.2 billion in 2025 and is projected to reach USD 52.8 billion by 2035, expanding at a CAGR of 3.1% during the forecast period.
Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/22086
Market Drivers
Rising Pressure to Reduce Drug Development Costs
The high cost and long timelines associated with conventional drug discovery are encouraging pharmaceutical companies to explore repurposing strategies. Existing medicines already have substantial information regarding their pharmacology, safety, and manufacturing characteristics. Using this information to investigate new indications can reduce some of the time and expense associated with developing an entirely new molecule.
Increasing Adoption of Artificial Intelligence in Drug Discovery
Artificial intelligence and computational drug repositioning technologies are transforming how researchers identify potential new applications for established medicines. Machine learning can analyze large datasets covering molecular interactions, disease pathways, clinical records, and published research to identify relationships that may not be obvious through traditional research methods. These capabilities are helping researchers narrow down promising candidates more efficiently.
Growing Burden of Chronic and Complex Diseases
The increasing prevalence of cancer, neurological disorders, cardiovascular diseases, infectious diseases, and rare conditions is creating demand for new therapeutic options. Drug repurposing provides researchers with an opportunity to investigate established medicines against diseases where treatment options remain limited. Oncology currently represents the largest therapeutic area, accounting for about 40.1% of 2024 revenue.
Patent Expirations and Pipeline Optimization
Patent expirations are creating pressure for pharmaceutical companies to maintain revenue and maximize the commercial potential of established products. Repurposing existing drugs for additional indications can help companies extend product lifecycles and address unmet clinical needs. This strategy is becoming particularly relevant as major pharmaceutical portfolios face significant patent-cliff exposure.
Supportive Regulatory Pathways
Regulatory mechanisms that allow developers to reference existing safety and efficacy information can make repurposing more attractive. Pathways such as the FDA’s 505(b)(2) route can allow sponsors to build on previously established information rather than repeating every stage of conventional development. Such frameworks can shorten development timelines and reduce unnecessary duplication of research.
Market Challenges
Limited Intellectual Property Protection
One of the major challenges associated with drug repurposing is the difficulty of establishing strong intellectual property protection for new uses of older medicines. When the underlying compound is already known or off patent, companies may face challenges in securing sufficient exclusivity to justify substantial clinical development investments.
Clinical Validation Requirements
Although a repurposed medicine may have an established safety profile, its effectiveness for a new disease or patient population still needs to be demonstrated. Clinical trials may be required to determine appropriate dosage, efficacy, safety, and treatment combinations. These requirements can still involve considerable time and financial resources.
Regulatory and Reimbursement Complexity
Different regulatory requirements across countries can make international development programs complicated. In addition, reimbursement policies may not always provide sufficient incentives for companies to invest in new indications for older medicines.
Data Integration and Quality Issues
Drug repurposing increasingly depends on large amounts of biological, clinical, genomic, and pharmaceutical data. Inconsistent datasets, limited access to proprietary information, data quality concerns, and interoperability issues can make computational screening and validation more difficult.
Browse In-depth Market Research Report on Drug Repurposing Market:
https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086
Market Segmentation
By Type:
Disease-Centric: This approach begins with a specific disease and identifies existing drugs that may have therapeutic potential against it.
Target-Centric: Target-centric repurposing investigates known biological targets and evaluates existing medicines that may interact with those targets.
Drug-Centric: Drug-centric approaches examine the known properties of an existing drug to identify additional diseases or therapeutic applications.
By Therapeutic Area:
Oncology: Oncology represents the largest therapeutic area, supported by continued research into kinase inhibitors, immunomodulators, and combination therapies.
CNS Disorders: Drug repurposing is increasingly being explored for neurological and neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.
Rare and Orphan Diseases: This segment represents a particularly attractive growth opportunity because existing medicines can potentially address diseases with limited treatment options.
Infectious Diseases: Repurposing established medicines remains an important research strategy for infectious diseases and antimicrobial resistance.
Cardiovascular Diseases: Established cardiovascular medicines are also being evaluated for additional therapeutic indications.
By Drug Molecules:
Small Molecules: Small-molecule drugs account for the largest share of the market, supported by established safety information and comparatively straightforward reformulation.
Peptides and Biologics: Biologics and peptides are gaining attention as computational technologies expand their ability to analyze complex biological interactions.
Others: Emerging approaches include nucleic-acid-based therapies, cell therapies, and other advanced therapeutic modalities.
By Development Stage:
Pre-Clinical: Computational screening and AI-supported research are helping identify potential candidates at earlier stages.
Phase I: Repurposed drugs entering Phase I are evaluated for safety and appropriate dosing in the new therapeutic context.
Phase II: Phase II represents an important stage for demonstrating proof of concept and evaluating therapeutic effectiveness.
Phase III: Candidates that demonstrate promising results move toward larger pivotal trials.
Approved/Marketed: Existing marketed medicines may undergo additional evaluation for label expansion and new indications.
By End-User:
Pharmaceutical and Biotechnology Companies: These organizations represent the largest end-user group and use repurposing to expand pipelines and extend product lifecycles.
Contract Research Organizations: CROs are increasingly supporting computational screening, clinical development, regulatory activities, and other outsourced repurposing services.
Academic and Research Institutes: Universities and research organizations contribute to target discovery, disease modeling, and translational research.
Others: Nonprofit organizations and philanthropic groups also support drug repurposing programs, particularly for diseases with limited commercial incentives.
Regional Insights
North America:
North America leads the global Drug Repurposing Market, accounting for approximately 48.7% of 2024 revenue. The region benefits from strong pharmaceutical and biotechnology ecosystems, advanced research infrastructure, venture capital availability, and established regulatory pathways. The United States remains a major center for computational drug discovery and repurposing research.
Europe:
Europe represents another important market, accounting for approximately 24.3% of 2024 revenue. Strong academic research networks, pharmaceutical capabilities, regulatory support, and collaborative research programs contribute to regional development. European organizations are increasingly using computational approaches and real-world evidence to identify new therapeutic opportunities.
Asia-Pacific:
Asia-Pacific is expected to be the fastest-growing regional market, with a projected CAGR of approximately 12.5% through 2035. Growing clinical-trial infrastructure in countries such as China and India, cost advantages, expanding pharmaceutical capabilities, and increasing government investment are supporting the region’s development.
Rest of the World:
Latin America, the Middle East, and Africa represent emerging opportunities as healthcare infrastructure improves and pharmaceutical research capabilities expand. Drug repurposing may be particularly valuable in these markets because it can potentially provide access to established therapies for additional diseases without requiring completely new drug discovery programs.
Key Players
Novartis
Pfizer
Recursion
BenevolentAI
Teva Pharmaceutical Industries
AbbVie
Viatris
Charles River Laboratories
Evotec
Anthem Biosciences
Future Outlook
The Drug Repurposing Market is expected to continue evolving as pharmaceutical companies seek faster and more cost-efficient approaches to therapeutic development. AI-powered drug discovery, network pharmacology, real-world evidence, and large-scale biological datasets are expected to improve the identification of promising repurposing candidates.
The strong focus on oncology and rare diseases is likely to remain an important market opportunity, while biologics and peptides may gain greater importance over the longer term. CROs are also expected to benefit as pharmaceutical companies outsource computational screening, clinical research, and regulatory activities. With the global market projected to reach USD 52.8 billion by 2035, drug repurposing is positioned to remain an important strategy for expanding therapeutic pipelines and addressing unmet medical needs.
Related Report:
Explore additional reports to understand evolving market landscapes:
About Market Research Future:
Market Research Future (MRFR) is a global market research company that provides comprehensive research and analysis across diverse industries and markets worldwide. The company focuses on delivering detailed market studies covering products, services, technologies, applications, end users, and market players at global, regional, and country levels. Its research is designed to help organizations understand market dynamics, identify opportunities, and make informed business decisions.
Follow Us:
LinkedIn | Twitter
Contact:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: sales@marketresearchfuture.com
Website: https://www.marketresearchfuture.com
